Fieldsend David
Brussels Office Manager, CARE for Europe, 205114 Rue Belliard, 1040-Brussels, Belgium.
Hum Reprod Genet Ethics. 2011;17(2):222-34. doi: 10.1558/hrge.v17i2.222.
This article, taken from a presentation to the 2011 European Association of Centres of Medical Ethics (EACME) annual conference, draws on both national legislation in European states and the Conventions of the Council of Europe as well as EU instruments such the Opinions of the European Group on Ethics in Science and New Technologies (EGE) and the Charter of Fundamental Rights to examine the current state of national and regional diversity in approaches to key bioethics issues and examines its evolution with reference to debates surrounding the development of key pieces of EU legislation and Council of Europe policy with bioethical implications. The relationship between the EU's genesis as a primarily economic and commercial governance entity--with its accompanying emphasis on the harmonization of technical standards--and its approach to diversity in national bioethical perspectives is also examined. Conclusions are drawn as to the relative success and desirability of the European consensus process in bioethics.
本文源自2011年在欧洲医学伦理中心协会(EACME)年度会议上的一场演讲,借鉴了欧洲各国的国家立法、欧洲理事会公约以及欧盟相关文件,如欧洲科学与新技术伦理小组(EGE)的意见和《基本权利宪章》,以审视各国及地区在关键生物伦理问题处理方式上的多样性现状,并参照围绕具有生物伦理影响的欧盟关键立法及欧洲理事会政策发展展开的辩论,探讨其演变过程。文中还研究了欧盟作为主要经济和商业治理实体的起源(及其对技术标准协调的重视)与它在国家生物伦理观念多样性问题上的处理方式之间的关系。最后得出关于欧洲生物伦理共识进程的相对成效及可取性的结论。